So-Young International Bets Big On Aesthetic Centers

So-Young International ((SY)) has held its Q4 earnings call. Read on for the main highlights of the call.

So-Young International’s latest earnings call painted a picture of a company in the midst of a high‑velocity strategic pivot, with its branded aesthetic centers driving record revenue growth and clear market leadership by clinic count. Management acknowledged that this expansion comes with near-term financial strain, but emphasized improving GAAP losses and a credible roadmap to balance rapid growth with profitability by 2026.

Record Quarterly Revenue Underscores Demand Recovery

Total fourth-quarter revenue climbed to RMB 451 million, up roughly 25% year over year and marking an all-time high for the company. Management framed this record as evidence of a strong demand rebound across its ecosystem, even as legacy platform segments weighed on the overall mix.

Aesthetic Centers Emerge as Core Growth Engine

Revenue from aesthetic treatment services surged to RMB 248.1 million, a jump of 205.3% year over year that pushed the segment above 50% of total revenue for the first time. This milestone signals a structural shift in So-Young’s business model toward a more vertically integrated, service-led platform.

Clinic Network Expansion Secures Market Leadership

By year-end 2025 So-Young operated 49 clinics, adding a net 10 centers in the fourth quarter and surpassing the 50-center mark early in 2026. Management said this footprint now ranks first nationwide by center count, giving the company scale advantages in branding, procurement and physician recruitment.

Explosive Growth in Treatments and Active Users

Verified treatment visits exceeded 125,000 in the quarter, up 178% year over year, while verified aesthetic treatments performed reached more than 289,400, up 168%. Total active users rose beyond 170,000, underscoring strong patient engagement and a growing demand funnel for the expanding clinic network.

Center-Level Economics Show Improving Quality of Growth

Seventeen mature centers generated RMB 102.5 million in revenue in the quarter, or about RMB 8.4 million each, while 19 growth centers delivered RMB 89 million, about RMB 4.7 million per site. Importantly, 25 centers were profitable and 39 produced positive operating cash flow, supporting management’s claim that unit economics strengthen as centers ramp.

Physician Expansion Bolsters Clinical Capabilities

The number of full-time physicians increased to 211 by quarter-end, up 41% from the end of the prior quarter and entirely drawn from public hospital backgrounds. With average experience above six years and more than 6,200 treatments per physician for those with at least a year at So-Young, management argued this depth underpins service quality and patient trust.

Scaled Supply Chain and Strong Product Mix

So-Young has partnered with 18 leading device suppliers, procuring nearly 1,400 devices, and 42 upstream partners for injectables, with cumulative procurement exceeding 700,000 units. The company highlighted that blockbuster products contributed over 37% of aesthetic revenue in Q4, enhancing both brand pull and treatment standardization.

Marketing Campaigns Drive Offline Visibility and Conversion

Fourth-quarter co-branded campaigns generated about 2 million on-site visits and roughly 40 million total exposures, particularly through placements in high-end shopping malls. Management said these initiatives validate the brand offline and help funnel traffic into flagship procedures, supporting higher conversion rates at the clinic level.

GAAP Loss Narrows as Cash Runway Remains Solid

Net loss attributable to So-Young narrowed to RMB 108.8 million from RMB 607.6 million a year earlier, with loss per ADS improving to RMB 1.08 from RMB 5.92. The company closed the year with RMB 936.4 million in cash, cash equivalents and short-term investments, which management views as sufficient to support its expansion plans.

Legacy Platform and Product Segments Under Pressure

Information and reservation services revenue fell 26.8% year over year to RMB 125.7 million, while medical product and maintenance sales slipped 19.9% to RMB 69.3 million and other services dropped 40.7% to RMB 17.7 million. The company attributed these declines to structural headwinds in its legacy marketplace, offset by faster growth in the aesthetic center business.

Rising Costs Reflect Front-Loaded Investments

Total cost of revenues increased 67.2% year over year to RMB 255.9 million, with aesthetic treatment service costs jumping 189.9% to RMB 189 million as new clinics ramped up. Management framed these higher consumable and operating costs as necessary upfront investments to build a nationwide network that can scale more efficiently over time.

Non-GAAP Loss Widens Amid Scaling Phase

Non-GAAP net loss attributable to So-Young widened to RMB 93.4 million, compared with RMB 53.2 million in the same period of 2024, reflecting the underlying operating drag of rapid build-out. Executives argued that the widening non-GAAP loss is temporary and will narrow as more centers move from growth to mature status.

Cash Balance Declines on Expansion Spend and Impairment

Total cash, restricted cash and short-term investments fell to RMB 936.4 million from RMB 1,253.2 million a year earlier, driven mainly by accelerated spending on new aesthetic centers. The company also booked a one-time impairment of goodwill and long-lived assets of RMB 19.7 million following its annual assessment.

Headwinds in Provider Subscriptions and Equipment Orders

Management noted that fewer medical service providers subscribed to its information services, and order volumes for medical equipment weakened, weighing on platform and product revenues. These pressures highlight the contrast between the legacy marketplace model and the rising contribution of So-Young’s owned and operated centers.

2026 Guidance: Balancing Aggressive Growth with Profitability

Looking ahead, So-Young guided Q4 2026 aesthetic treatment services revenue to RMB 258–278 million, implying year-over-year growth of roughly 171.2%–181.3%, and plans to open at least 35 new centers in 2026. Management expects margin expansion as more centers mature, supplier partnerships deepen, physician productivity rises and the company deploys its RMB 936.4 million cash balance toward scaling with a clear path to sustainable profitability.

So-Young’s earnings call showcased a company leaning hard into its high-growth aesthetic center strategy while accepting short-term financial pain to build a defensible market position. For investors, the key question is execution: if maturing clinics deliver the promised margins, today’s elevated costs and non-GAAP losses could give way to a more profitable, scaled platform by 2026.